Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
130 studies found for:    "HIV Preventive Vaccine" [CONDITION]
Show Display Options
RSS Create an RSS feed from your search for:
"HIV Preventive Vaccine" [CONDITION]
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Active, not recruiting Safety of and Immune Response to a DNA HIV Vaccine Boosted With a Modified Vaccinia HIV Vaccine and Protein HIV Vaccine in Healthy Adults
Conditions: HIV Seronegativity;   HIV Preventive Vaccine
Interventions: Biological: MVA-C + gp140/MF59;   Biological: DNA-C2 + MVA-C;   Biological: DNA-C2 + MVA-C + gp140/MF59
2 Completed Safety of and Immune Response to an HIV-1 DNA Vaccine (VRC HIVDNA009-00-VP) in HIV Uninfected Adults
Condition: HIV Infections
Intervention: Biological: VRC-HIVDNA009-00-VP
3 Completed Safety of and Immune Response to a DNA HIV Vaccine Followed By Boosting With One of Two Serotypes of Adenoviral Vector HIV Vaccine in Healthy Adults
Condition: HIV Infections
Interventions: Biological: VRC-HIVADV027-00-VP;   Biological: VRC-HIVADV038-00-VP;   Biological: VRC-HIVDNA044-00-VP
4 Completed Safety of and Immune Response to an HIV Vaccine (SF-2 gp120) With or Without MTP-PE/MF59 Adjuvant
Condition: HIV Infections
Interventions: Biological: rgp120/HIV-1 SF-2;   Biological: MTP-PE/MF59
5 Completed A Phase I Multicenter, Randomized, Double-Blind Trial to Evaluate the Safety and Immunogenicity of Recombinant Vaccinia Virus Expressing the Envelope Glycoproteins of Human Immunodeficiency Virus
Condition: HIV Infections
Interventions: Biological: HIVAC-1e;   Biological: gp160 Vaccine (MicroGeneSys)
6 Completed A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of 200 Mcg of gp120 (CHO) BIOCINE in MF59 Emulsion Versus the Emulsion Control: Three Injections at 0, 1, and 6 Months
Condition: HIV Infections
Intervention: Biological: rgp120/HIV-1 SF-2
7 Withdrawn Safety of and Immune Response to an HIV DNA Plasmid Vaccine Followed by HIV Adenoviral Vector Vaccine in Healthy African Adults
Condition: HIV Infections
Interventions: Biological: VRC-HIVDNA016-00-VP;   Biological: VRC-HIVADV014-00-VP;   Biological: Vaccine placebo
8 Active, not recruiting Immune Response to an HIV DNA Plasmid Vaccine Prime Followed by Adenovirus Boost in HIV-uninfected Individuals
Condition: HIV Infections
Interventions: Biological: VRC-HIVDNA-016-00-VP;   Biological: VRCHIVADV014-00-VP
9 Completed The Effectiveness of Human Antibodies in Influencing an AIDS-Like Disease in Monkeys
Condition: HIV Infections
Interventions: Biological: gp160 MN/LAI-2;   Biological: Aluminum hydroxide
10 Withdrawn Safety and Effectiveness of Two Different Formulations of an HIV Vaccine in Infants Born to HIV-Infected Women
Conditions: HIV Infections;   HIV Seronegativity
Interventions: Biological: Aluminum hydroxide;   Biological: QS-21;   Biological: MN rsgp120/HIV-1
11 Completed A Phase I Study to Evaluate the Safety and Immunogenicity of Recombinant HIV-1 Envelope Antigen in Children Born to HIV-Infected Mothers
Conditions: HIV Infections;   HIV Seronegativity
Interventions: Biological: rgp120/HIV-1MN;   Biological: rgp120/HIV-1 SF-2;   Biological: Placebo version of  rgp120/HIV-1MN;   Biological: Placebo version of rgp120/HIV-1SF2
12 Completed Study to Compare the Immunogenicity and Safety of Two HIV Preventive Vaccinations in Healthy Volunteers
Condition: HIV Infections
Interventions: Biological: DNA-C;   Biological: NYVAC-C
13 Completed Safety of and Immune Response to a New HIV Vaccine: HIV CTL MEP
Condition: HIV Infections
Interventions: Biological: HIV CTL MEP administered with RC529-SE adjuvant;   Drug: GM-CSF
14 Completed A Phase I, Multicenter, Clinical Trial to Evaluate the Safety and Immunogenicity of Vaccinia-Derived MN HIV-1 Recombinant Envelope Glycoprotein (rgp160) of Human Immunodeficiency Virus at Two Different Vaccination Schedules
Condition: HIV Infections
Intervention: Biological: gp160 Vaccine (Immuno-AG)
15 Completed ALVAC-HIV vCP1452 Alone and Combined With MN rgp120
Conditions: HIV Infections;   HIV Seronegativity
Interventions: Biological: ALVAC(2)120(B,MN)GNP (vCP1452);   Biological: MN rgp120/HIV-1;   Biological: ALVAC(2)120(B,MN)GNP (vCP1452) placebo;   Biological: MN rgp120/HIV-1  placebo
16 Completed Safety of and Immune Response to a DNA Vaccine and a Recombinant HIV-1-MVA Vaccine, Separately and in Combination, in Healthy Adults
Condition: HIV Infections
Interventions: Biological: EP-1233;   Biological: MVA-mBN32
17 Completed Safety of and Immune Response to a Combination HIV Vaccine Regimen in HIV Uninfected Adults
Condition: HIV Infections
Interventions: Biological: Clade B gag DNA/PLG and env DNA/PLG Microparticles;   Biological: Clade B Recombinant, Oligomeric gp140/MF59 Adjuvant
18 Completed Safety of and Immune Response to an HIV-1 Vaccine Boost (VRC-HIVADV014-00-VP) in HIV Uninfected Adults Who Participated in HVTN 052
Condition: HIV Infections
Intervention: Biological: VRC-HIVADV014-00-VP
19 Completed Safety of and Immune System Response to an HIV Vaccine (EP HIV-1090) in HIV Uninfected Adults
Condition: HIV Infections
Intervention: Biological: EP HIV-1090
20 Completed Safety of and Immune Response to an HIV Preventive Vaccine (HIV-1 Gag DNA Alone or With IL-15 DNA) Given With or Without 2 Different Booster Vaccinations in HIV Uninfected Adults
Condition: HIV Infections
Interventions: Biological: HIV-1 gag DNA;   Biological: IL-15 DNA adjuvant;   Biological: IL-12 DNA adjuvant

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years